Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Allergan's Eyelash Drug Gets Good News from FDA - Happi
Company News

Allergan’s Eyelash Drug Gets Good News from FDA

Once-a-day treatment enhances lashes.

Shares of cosmetic drugmaker Allergan climbed Monday on news that a panel of government advisers favorably reviewed the company’s experimental drug to enhance eyelashes.

Allergan, which makes Botox anti-wrinkle injections, has asked the Food and Drug Administration to approve its Lumigan formula to enhance eyelashes for patients 18 and older. The drug is designed to be applied once daily to the base of the lashes.

On Friday a Food and Drug Administration panel of experts voted unanimously that the drug’s benefits outweigh its risks. The agency is not required to follow the panel’s advice, but it normally does.

Lazard Capital Markets analyst Sean Lavin said he expects the FDA to approve Lumigan in the second half of 2009. While Allergan expects annual sales to reach $500 million annually, Lavin forecasted a modest $50 million in sales for the drug in 2010 — its first full year on the market.

Commenting on the company’s rising stock, Lavin wrote “this could be an overreaction given that the product will likely represent around 1 percent of revenue in 2010.”

Allergan makes the bulk of its profit from eye-care products, Botox injections and breast implants.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters